



JFW

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/581,340 ✓

Filing Date

June 2, 2006

First Named Inventor

David S. GARVEY

Art Unit

N/A

Examiner Name

Not Yet Assigned

Attorney Docket Number

0102258.00368US2

ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Reply to Missing Parts/
Incomplete Application☐ Reply to Missing Parts under
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication
to TC☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please
Identify below):

Return Receipt Postcard

73 References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

WILMER CUTLER PICKERING HALE AND DORR LLP

Signature

Printed name

Jacob Steven Oyloe

Date

August 3, 2007


Reg. No.

58,686

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being hand delivered on the date shown below to: Customer Window, Mail Stop Amendment, U.S. Patent and Trademark Office, Randolph Building, 401 Dulany Street, Alexandria, Virginia 22314.

Dated: August 3, 2007

Signature: _____ (Jacob Steven Oyloe)



Docket No.: 0102258.00368US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David S. GARVEY et al. Confirmation No.:
Application No.: 10/581,340 Art Unit: N/A
Filed: June 2, 2006 Examiner: Not Yet Assigned
Title: NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS,
COMPOSITIONS AND METHODS OF USE

Customer Window, Mail Stop Amendment
U.S. Patent and Trademark Office
Randolph Building
401 Dulany Street
Alexandria, Virginia 22314

INFORMATION DISCLOSURE STATEMENT (IDS)


Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.


Dated: August 3, 2007

Respectfully submitted,



Jacob Steven Oylo
Registration No.: 58,686
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
1875 Pennsylvania Avenue, NW
Washington, DC 20006
(202) 663-6000 (telephone)
(202) 663-6363 (facsimile)



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/581,340
				Filing Date	June 2, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	0102258.00368US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-4,780,401	10-25-1988	Heusser et al.	
	AB*	US-4,845,079	07-04-1989	Luly et al.	
	AC*	US-4,885,292	12-05-1989	Ryono et al.	
	AD*	US-4,894,437	01-16-1990	TenBrink	
	AE*	US-4,980,283	12-25-1990	Huang et al.	
	AF*	US-5,034,512-A	07-23-1991	Hudspeth et al.	
	AG*	US-5,036,053-A	07-30-1991	Himmelsbach et al.	
	AH*	US-5,036,054-A	07-30-1991	Kaltenbronn et al.	
	AI*	US-5,055,466-A	10-08-1991	Weller, III et al.	
	AJ*	US-5,063,207-A	11-05-1991	Doherty et al.	
	AK*	US-5,063,208-A	11-05-1991	Rosenberg et al.	
	AL*	US-5,064,965-A	11-12-1991	Ocain et al.	
	AM*	US-5,066,643-A	11-19-1991	Abeles et al.	
	AN*	US-5,071,837-A	12-10-1991	Doherty et al.	
	AO*	US-5,075,451-A	12-24-1991	Ocain et al.	
	AP*	US-5,089,471-A	02-18-1992	Hanson et al.	
	AQ*	US-5,095,006-A	03-10-1992	Bender et al.	
	AR*	US-5,095,119-A	03-10-1992	Ocain et al.	
	AS*	US-5,098,924-A	03-24-1992	Poss	
	AT*	US-5,104,869	04-14-1992	Albright et al.	
	AU*	US-5,106,835-A	04-21-1992	Albright et al.	
	AV*	US-5,114,937-A	05-19-1992	Hamby et al.	
	AW*	US-5,116,835-A	05-26-1992	Ruger et al.	
	AX*	US-5,120,737	06-09-1992	Suzuki et al.	
	AY*	US-5,256,697	10-26-1993	Miller et al.	
	AZ*	US-5,262,165	11-16-1993	Govil et al.	
	AA1*	US-5,284,872-A	02-08-1994	Sandrock et al.	
	AB1*	US-5,344,991-A	09-06-1994	Reitz et al.	
	AC1*	US-5,380,738-A	01-10-1995	Norman et al.	
	AD1*	US-5,380,758-A	01-10-1995	Stamler et al.	
	AE1*	US-5,393,790-A	02-28-1995	Reitz et al.	
	AF1*	US-5,409,944-A	04-25-1995	Black et al.	
	AG1*	US-5,428,061-A	06-27-1995	Sandrock et al.	
	AH1*	US-5,434,178-A	07-18-1995	Talley et al.	
	AI1*	US-5,436,265-A	07-25-1995	Black et al.	
	AJ1*	US-5,466,823	11-14-1995	Talley et al.	
	AK1*	US-5,474,995-A	12-12-1995	Ducharme et al.	
	AL1*	US-5,510,368-A	04-23-1996	Lau et al.	
	AM1*	US-5,536,752-A	07-16-1996	Ducharme et al.	
	AN1*	US-5,550,142	08-27-1996	Ducharme et al.	
	AO1*	US-5,552,422	09-03-1996	Gauthier et al.	
	AP1*	US-5,604,253	02-18-1997	Lau et al.	
	AQ1*	US-5,604,260	02-18-1997	Guay et al.	
	AR1*	US-5,639,780	06-17-1997	Lau et al.	
	AS1*	US-5,650,447	07-22-1997	Keefer et al.	
	AT1*	US-5,661,129	08-26-1997	Feelisch et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/581,340
				Filing Date	June 2, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	5	Attorney Docket Number	0102258.00368US2

	AU1*	US-5,703,073-A	12-30-1997	Garvey et al.	
	AV1*	US-5,807,847	09-15-1998	Thatcher et al.	
	AW1*	US-5,859,053	01-12-1999	Lesur et al.	
	AX1*	US-5,874,437	02-23-1999	Garvey et al.	
	AY1*	US-5,876,916	03-02-1999	Brunengraber et al.	
	AZ1*	US-5,883,122	03-16-1999	Thatcher et al.	
	AA2*	US-5,910,316	06-08-1999	Keefer et al.	
	AB2*	US-5,932,538	08-03-1999	Garvey et al.	
	AC2*	US-5,932,598	08-03-1999	Talley et al.	
	AD2*	US-5,948,433	09-07-1999	Burton et al.	
	AE2*	US-5,958,926	09-28-1999	Garvey et al.	
	AF2*	US-5,994,294	11-30-1999	Garvey et al.	
	AG2*	US-6,010,715	01-04-2000	Wick et al.	
	AH2*	US-6,057,347	05-02-2000	Garvey et al.	
	AI2*	US-6,071,531	06-06-2000	Jona et al.	
	AJ2*	US-6,133,272	10-17-2000	Garvey et al.	
	AK2*	US-6,172,068	01-09-2001	Garvey et al.	
	AL2*	US-6,177,428	01-23-2001	Garvey et al.	
	AM2*	US-6,197,778	03-06-2001	Garvey et al.	
	AN2*	US-6,197,782	03-06-2001	Garvey et al.	
	AO2*	US-6,211,179	04-03-2001	Garvey et al.	
	AP2*	US-6,221,881	04-24-2001	Garvey et al.	
	AQ2*	US-6,232,321	05-15-2001	Garvey et al.	
	AR2*	US-6,232,336	05-15-2001	Hrabie et al.	
	AS2*	US-6,297,260	10-02-2001	Bandarage et al.	
	AT2*	US-6,316,457	11-13-2001	Garvey et al.	
	AU2*	US-6,331,542	12-18-2001	Carr et al.	
	AV2*	US-6,455,542-A1	09-24-2002	Anggard et al.	
	AW2*	US-6,633,272	10-14-2003	Kumagawa et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-0574726	12-22-1993	Cassella Farbwerke Mainkur Ag		
	BB	EP-0683159	11-22-1995	Cassella Farbwerke Mainkur Ag		
	BC	WO-0028988	05-25-2000	Nitromed Inc et al.		
	BD	WO-0051988	09-08-2000	Nicox Sa et al.		
	BE	WO-0054756	09-21-2000	Univ Kingston		
	BF	WO-0061537	10-19-2000	Nicox Sa et al.		
	BG	WO-0061541	10-19-2000	Nicox Sa et al.		
	BH	WO-0061604	10-19-2000	Nicox Sa et al.		
	BI	WO-0072838	12-07-2000	Astrazeneca Ab et al.		
	BJ	WO-0100563	01-04-2001	Nicox Sa et al.		
	BK	WO-0104082	01-18-2001	Nicox Sa et al.		
	BL	WO-0110814	02-15-2001	Nicox Sa et al.		
	BM	WO-0112584	02-22-2001	Nicox Sa et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/581,340
				Filing Date	June 2, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	0102258.00368US2

	BN	WO-0124793	04-12-2001	Masstrace Inc et al.		
	BO	WO-0145703	06-28-2001	Nitromed Inc et al.		
	BP	WO-0187343	11-22-2001	Merck Frosst Canada Inc et al.		
	BQ	WO-02074301	09-26-2002	Univ Pittsburgh et al.		
	BR	WO-02090314	11-14-2002	Galileo Lab Inc et al.		
	BS	WO-0211707	02-14-2002	Nicox Sa et al.		
	BT	WO-0230866	04-18-2002	Nicox Sa et al.		
	BU	WO-03013432	02-20-2003	Nitromed Inc et al.		
	BV	WO-03017996	03-06-2003	Cellular Sciences Inc et al.		
	BW	WO-9309806	05-27-1993	Brigham & Womens Hospital		
	BX	WO-9401422	01-20-1994	Chiesi Farma Spa et al.		
	BY	WO-9403387	02-17-1994	Donisthorpe & Company Limited et al.		
	BZ	WO-9403421	02-17-1994	Cal Int Ltd et al.		
	BA1	WO-9404484	03-03-1994	Corlay SI et al.		
	BB1	WO-9412463	06-09-1994	Hct Health Care Trading Ltd et al.		
	BC1	WO-9415723	07-21-1994	Derrick Mfg Corp		
	BD1	WO-9420480	09-15-1994	Merck Frosst Canada Inc et al.		
	BE1	WO-9426731	11-24-1994	Merck Frosst Canada Inc et al.		
	BF1	WO-9427980	12-08-1994	Searle & Co et al.		
	BG1	WO-9500501	01-05-1995	Merck Frosst Canada Inc et al.		
	BH1	WO-95/09831	04-13-1995	Nicox Ltd et al.		
	BI1	WO-9515316	06-08-1995	Searle & Co et al.		
	BJ1	WO-9519952	07-27-1995	Byk Nederland Bv et al.		
	BK1	WO-9530641	11-16-1995	Nicox Ltd et al.		
	BL1	WO-9603387	02-08-1996	Searle & Co et al.		
	BM1	WO-9603388	02-08-1996	Searle & Co et al.		
	BN1	WO-9606840	03-07-1996	Merck Frosst Canada Inc et al.		
	BO1	WO-9621667	07-18-1996	Merck Frosst Canada Inc et al.		
	BP1	WO-9631509	10-10-1996	Glaxo Group Ltd et al.		
	BQ1	WO-9636623	11-21-1996	Merck Frosst Canada Inc et al.		
	BR1	WO-9714691	04-24-1997	Merck Frosst Canada Inc et al.		
	BS1	WO-9716435	05-09-1997	Merck Frosst Canada Inc et al.		
	BT1	WO-9727749	08-07-1997	Nitromed Inc et al.		
	BU1	WO-9734856	09-25-1997	Univ Case Western Reserve		
	BV1	WO-9746521	12-11-1997	Univ Kingston et al.		
	BW1	WO-9819672	05-14-1998	Nitromed Inc et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/581,340
				Filing Date	June 2, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	0102258.00368US2

	BX1	WO-9821193	05-22-1998	Nicox Sa et al.		
	BY1	WO-9851277	11-19-1998	Univ Case Western Reserve		
	BZ1	WO-9964417	12-16-1999	Zeneca Ltd et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Arzneim. Forsch. Drug Res, 47 (II), No. 7, p. 847-854 (1997)	
	CB	Boschi, et al., "New Potential Uroselective NO-Donor α_1 -Antagonists," <i>J. Med. Chem.</i> , Vol. 46, p. 3762-3765 (2003)	
	CC	Brideau, et al., "A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors," <i>Inflamm Res.</i> , 45: 68-74 (1996)	
	CD	Cena, et al., "Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin," <i>J. Med. Chem.</i> , Vol. 46, p. 747-754 (2003)	
	CE	Cerecetto, et al., "1,2,5-Oxadiazole N-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs: Structure-Activity Relationships," <i>J. Med. Chem.</i> , Vol. 42, p. 1941-1950 (1999)	
	CF	Di Stilo, et al., "New 1,4-Dihydropyridines Conjugated to Furoxanyl Moieties, Endowed with Both Nitric Oxide-like and Calcium Channel Antagonist Vasodilator Activities," <i>J. Med. Chem.</i> , Vol. 41, p. 5393-5401 (1998)	
	CG	Drug facts and comparisons, (1993 Ed.)	
	CH	Fruttero, et al., "The Furoxan System as a Useful Tool for Balancing 'Hybrids' with Mixed α_1 -Antagonist and NO-like Vasodilator Activities," <i>J. Med. Chem.</i> , Vol. 38, p. 4944-4949 (1995)	
	CI	Fruttero, et al., "Unsymmetrically Substituted Furoxans, Part 11[1]. Methylfurosancarbaldehydes," <i>J. Heterocyclic Chem.</i> , 26: 1345-1347 (1989)	
	CJ	Goodman and Gilman's, <i>The Pharmacological Basis of Therapeutics</i> (9th Edition), McGraw-Hill, p. 617-657 (1995)	
	CK	Goodman & Gilman's <i>The Pharmacological Basis of Therapeutics</i> (9th Edition), McGraw-Hill, p. 901-915 (1995)	
	CL	Greene and Wuts, <i>Protective Groups in Organic Synthesis</i> , Third Edition, John Wiley & Sons, New York (1999)	
	CM	Ignarro, et al., "Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, p. 9265-9269 (1987)	
	CN	Keaney, et al., "Diabetes, Oxidative Stress, and Platelet Activation," <i>Circulation</i> , 99:189-191 (1999)	
	CO	Merck Index, 13th Edition	
	CP	Moharram, et al., "Design and Synthesis of 3' - and 5' -O-(3-Benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines; Biological Evaluation as Hybrid Nitric Oxide Donor-Nucleoside Anticancer Agents," <i>J. Med. Chem.</i> , Vol. 47, p. 1840-1846 (2004)	
	CQ	Oae, et al., <i>Org. Prep. Proc. Int.</i> , Vol. 15, No. 3, p. 165-198 (1983)	
	CR	Palmer, et al., "Nitric oxide release accounts for the biological activity of endothelium-derived	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<div>Substitute for form 1449/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(Use as many sheets as necessary)</div>				Complete If Known	
				Application Number	10/581,340
				Filing Date	June 2, 2006
				First Named Inventor	David S. GARVEY
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	0102258.00368US2

		relaxing factor," <i>Nature</i> , Vol. 327, p. 524-526 (1987)	
	CS	<i>The Physicians' Desk Reference</i> , (49th Ed.), Medical Economics (1995)	
	CT	Visentin, et al., "New 1,4-Dihydropyridines Endowed with NO-Donor and Calcium Channel Agonist Properties," <i>J. Med. Chem.</i> , Vol. 47, p. 2688-2693 (2004)	
	CU	Wang, et al., "Nitric Oxide Donors: Chemical Activities and Biological Applications," <i>Chem. Rev.</i> , 102: 1091-1134 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--